Full Text View
Tabular View
No Study Results Posted
Related Studies
Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas
This study has been terminated.
Study NCT00493454   Information provided by M.D. Anderson Cancer Center

First Received on June 27, 2007.   Last Updated on February 20, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Lymphoma, B-Cell
Lymphoma, B-Cell, Marginal Zone
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Zevalin
Rituximab
^111 In Ibritumomab Tiuxetan
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Biogen Idec


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services